Motley Fool Asset Management LLC Has $390,000 Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Motley Fool Asset Management LLC cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 8.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,035 shares of the biopharmaceutical company’s stock after selling 196 shares during the period. Motley Fool Asset Management LLC’s holdings in Alnylam Pharmaceuticals were worth $390,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the company. Semanteon Capital Management LP acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $308,000. Bank Julius Baer & Co. Ltd Zurich bought a new position in Alnylam Pharmaceuticals during the fourth quarter worth $416,000. State of New Jersey Common Pension Fund D increased its holdings in shares of Alnylam Pharmaceuticals by 2.3% in the fourth quarter. State of New Jersey Common Pension Fund D now owns 73,259 shares of the biopharmaceutical company’s stock valued at $14,023,000 after purchasing an additional 1,674 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. raised its position in shares of Alnylam Pharmaceuticals by 5.8% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 3,575 shares of the biopharmaceutical company’s stock valued at $684,000 after purchasing an additional 195 shares during the period. Finally, GAMMA Investing LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at about $52,000. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Trading Down 0.3 %

Shares of ALNY opened at $143.31 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $218.88. The stock has a fifty day moving average of $150.29 and a 200-day moving average of $165.97.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.20) by $0.10. The firm had revenue of $439.72 million during the quarter, compared to the consensus estimate of $439.38 million. Alnylam Pharmaceuticals’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($1.68) earnings per share. Sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -4.46 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on ALNY. Chardan Capital decreased their target price on Alnylam Pharmaceuticals from $250.00 to $225.00 and set a “buy” rating on the stock in a research report on Friday, February 16th. Royal Bank of Canada restated an “outperform” rating and issued a $235.00 price target on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. BMO Capital Markets reaffirmed an “outperform” rating and set a $234.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 27th. Morgan Stanley cut their price objective on shares of Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, February 13th. Finally, JPMorgan Chase & Co. increased their target price on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the stock a “neutral” rating in a research report on Thursday, February 1st. Eight investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $215.88.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.